11 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26709102	142	Discovery of Vibegron: A Potent and Selectiveß3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.	Merck Research Laboratories
26125514	40	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Humanß3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.	Asahi Kasei Pharma
11311067	38	Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.	Kissei Pharmaceutical
24900353	6	Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity.	TBA
7562902	114	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.	Smithkline Beecham Pharmaceuticals
20812727	157	Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.	National Institute of Mental Health
	3	Asymmetric synthesis of FR165914: A novel β3-adrenergic agonist with a benzocycloheptene structure	TBA
17911024	37	Potent oxindole based human beta3 adrenergic receptor agonists.	Eli Lilly
17632003	55	Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.	Pfizer
16931005	21	Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.	Eli Lilly
1354264	19	Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.	American Cyanamid